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Introduction
Hemoglobin disorders, particularly β-thalassemia and sickle
cell disease (SCD), are the most common single gene disorders
worldwide.1 They are caused by mutations in the β-globin
locus resulting in abnormal or reduced rates of hemoglobin A
(HbA) production. Clinical symptoms include anemia, infarc-
tion, bone marrow expansion and splenomegaly. The disease
is lethal at a very early age, but patients receiving up to date
treatment have a life expectancy of approximately four
decades.2,3
In humans, fetal γ-globin and adult β-globin are the major β-
like globins. They associate with α-globin chains to produce
HbF (α2γ2) during the fetal period and HbA (α2β2) in adult life.
This developmentally regulated globin gene expression pat-
tern, known as globin switching, has been the subject of
intense research during the last 30 years, mainly because reac-
tivation of γ-globin expression would be beneficial to β-hemo-
globinopathy patients. In β-thalassemia patients, γ-globin
expression can reduce α-globin chain precipitation and com-
pensate for the lack of β-globin chains through the formation
of HbF. In SCD patients, high HbF reduces hemoglobin poly-
merization. This prevents sickling and improves the life span
of the erythrocytes, thereby ameliorating disease symptoms.4
Several drugs can induce γ-globin gene expression resulting
in increased HbF production and amelioration of the disease.
Three well-known HbF-inducing agents are sodium butyrate (a
histone deacetylase inhibitor),5 5-azacytidine (a DNA
demethylating agent)6 and hydroxyurea (a ribonucleotide
reductase inhibitor).7 Hydroxyurea (HU) is FDA approved for
treatment of SCD patients and it is also widely used for β-tha-
lassemia.8-12 How HU induces HbF production is poorly under-
stood. Mechanisms proposed for the induction of HbF by HU
include rapid erythroid regeneration, increased erythropoietin
(EPO) production, apoptosis, nitric oxide (NO) production,13
increased guanylate cyclase activity13 and activation of the p38
MAPK pathway.14 Induction of HbF by HU in β-thalassemia
patients was reported to be of similar magnitude as found in
the cells of normal individuals (1.3- to 3.5-fold) and SCD
patients (2- to 5-fold). In erythroid progenitor cells treated with
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β-thalassemia is caused by mutations in the β-globin locus resulting in loss of, or reduced, hemoglobin A (adult
hemoglobin, HbA, α2β2) production. Hydroxyurea treatment increases fetal γ-globin (fetal hemoglobin, HbF, α2γ2)
expression in postnatal life substituting for the missing adult β-globin and is, therefore, an attractive therapeutic
approach. Patients treated with hydroxyurea fall into three categories: i) ‘responders’ who increase hemoglobin to
therapeutic levels; (ii) ‘moderate-responders’ who increase hemoglobin levels but still need transfusions at longer
intervals; and (iii) ‘non-responders’ who do not reach adequate hemoglobin levels and remain transfusion-depen-
dent. The mechanisms underlying these differential responses remain largely unclear. We generated RNA expres-
sion profiles from erythroblast progenitors of 8 responder and 8 non-responder β-thalassemia patients. These pro-
files revealed that hydroxyurea treatment induced differential expression of many genes in cells from non-respon-
ders while it had little impact on cells from responders. Part of the gene program up-regulated by hydroxyurea in
non-responders was already highly expressed in responders before hydroxyurea treatment. Baseline HbF expression
was low in non-responders, and hydroxyurea treatment induced significant cell death. We conclude that cells from
responders have adapted well to constitutive stress conditions and display a propensity to proceed to the erythroid
differentiation program.
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ABSTRACT
HU in vitro, HbF induction was comparable to the increase
of HbF in peripheral blood of SCD patients following HU
therapy in vivo.15 The majority of patients increase HbF pro-
duction upon HU treatment.4 However, HbF baseline and
response magnitude among the patients is highly variable.
The absolute HU response and the HbF baseline is likely
dependent on genetic factors that modulate different regu-
latory pathways and trans-acting factors involved in γ-glo-
bin production. 
Correlation of multiple single nucleotide polymorphisms
(SNPs) with high HbF baseline has been reported in several
studies.4 The XmnI (G)γ SNP at -158 (C>T) for instance is
associated with high HbF baseline in SCD and β-tha-
lassemia patients.16 The correlation between gene muta-
tions and clinical response to HU has been investigated in
many articles. While the β-globin mutations are not associ-
ated with HbF response to HU therapy, the Xmn I polymor-
phism has yielded inconsistent results. A SNP association
study reported multiple significantly associated SNPs with
HbF response to HU.10-12,17-21 However, a recent study in a
large group of SCD children evaluated the effect of previ-
ously reported pharmacogenetic variables on HU response
and found no significant association between any β-globin
haplotypes (including XmnI) with HbF maximum HU toler-
ated dose after adjustment for HbF baseline.22 A total of 23
previously reported SNPs17 for high HbF baseline were also
examined for their association with HU pharmacodynam-
ics variables and only 2 SNPs (in the ARG1 and ARG2
genes) were found to be significantly associated with the
change in HbF and maximum HU tolerated dose.22
Regulation of γ-globin gene expression is complex and
can be influenced by different regulatory pathways, genet-
ic- and environmental factors. The net outcome of these
determines the response to HU.4 We hypothesized that
some of the regulatory mechanisms may be deduced from
the comparison of the expression profiles of cultured
human erythroid progenitor cells (HEP) derived from HU
‘responder’ (R-HEP) and ‘non-responder’ (NR-HEP)
patients. In addition, data from such an approach may help
to understand the mechanism by which HU induces γ-glo-
bin expression. It may also help explaining the difference
between ‘responders’ (R) and ‘non-responders’ (NR) regard-
ing baseline levels of HbF and factors that are involved in γ-
globin induction. Only a few such studies have been report-
ed. One study reported expression profiling of peripheral
blood mononuclear cells to characterize the role of circulat-
ing leukocytes in sickle cell pathogenesis.23 The expression
profile of these cells is, therefore, not informative for the
HbF response to HU in erythroid progenitor cells. Other
studies on the effect of HU in SCD patients show decreased
expression of adhesion molecules in vascular endothelial
and red cells,24-25 its stimulating effect on proinflammatory
gene expression,26 and several other pathways.27-28 To our
knowledge, none of these studies address the differential
HU response in β-thalassemia. Here we studied two groups
of β-thalassemia patients: those who did not respond suffi-
ciently to HU treatment and remained fully dependent on
regular blood transfusions and those who become transfu-
sion-independent upon HU treatment. We expanded HEP
cells from peripheral blood of tesponder and non-responder
patients and compared their proliferation, hemoglobin pro-
duction and gene expression profiles in the presence and
absence of HU. Our data shows that R-HEPs showed a rel-
atively high baseline level of HbF compared to that of NR-
HEPs. NR-HEPs change the expression pattern of a large
number of genes upon HU treatment, while R-HEPs
showed only minor changes after treatment. Differential
gene expression profiles of these two groups indicated that
high HbF was associated with a continuously activated
stress response, and with genes that protect from stress-
induced apoptosis. This suggests that HU is effective in R
patients because their baseline HbF levels are relatively high
and their erythroblasts have already activated a stress
response program that protects them from the cytotoxic
effects of HU. Moreover, R-HEPs displayed a propensity to
proceed to terminal erythroid differentiation.
Design and Methods
Patients
The studies reported here were approved by the local medical
ethical review committee and written informed consent was
obtained from all the participating patients or their guardians. A
large collection of β-thalassemic patients with milder phenotype,
higher Hb level, less or no skeletal deformity, receiving a similar
amount of blood transfusions on regular bases were monitored for
their clinical manifestation and response to hydroxyurea (HU)
treatment. Transfusions were temporarily stopped at the start
point of HU treatment, and hematologic indexes were analyzed at
different time points. Detailed clinical data, molecular analysis,
hematologic indexes, transfusion and treatments are provided in
the Online Supplementary Design and Methods and Online
Supplementary Table S1. Two distinct groups were defined based on
their response to HU: ‘responders (R)’ with a good response to HU
treatment resulting in maintaining the mean hemoglobin level up
to 8.5 g/dl (our threshold for transfusion) resulting in transfusion
independency. ‘Non-responders (NR)’ with a poor response to HU
treatment showing a mean Hb of less than 8.5 g/dl. This group of
patients developed side effects to HU therapy, had discomfort
using the drug, and no or very little change in transfusion intervals
during the treatment period. Peripheral blood was collected from
the patients at the same time for culturing of erythroid progenitors
used for subsequent studies. 
Mutations in the α- and β-globin genes and the -158 XmnI Gγ-
globin gene (C>T SNP) were determined as described previous-
ly.29,30 Since positive correlation between α-globin deletions and
good response to HU therapy is reported,12,19,31 patients with
mutated or deleted α-globin alleles were excluded from the study.
Although a high HbF base line is correlated with the XmnI poly-
morphism as well other SNPs, HbF response to HU therapy does
not seem to be correlated with the Xmn I polymorphism as well as
β-globin gene mutation.10,18-19 We, therefore, did not bias our study
for these variables. We selected 8 patients from each group who
comply with the above mentioned criteria for microarray analysis. 
Hematologic analysis
A complete blood count was carried out on a hematology count-
er and standard methods were used for peripheral blood smear
examination and reticulocyte count. The variant hemoglobin test-
ing system was used for hemoglobin analysis. 
Cell culture
HEPs were cultured essentially as published32 (see Online
Supplementary Design and Methods for details). The cultures were
expanded until Day 10 resulting in a homogenous population of
erythroid progenitor cells.33 After Day 10, the cells were divided
into control and HU treated (100 μM/mL HU) and the cultures
were continued. RNA was isolated 48 h after HU treatment; the
remaining cells were kept in culture for another three days to
determine total hemoglobin, HbF and growth rates.
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Cell morphology
Cell morphology was analyzed using cytospins stained with his-
tological dyes and neutral benzidine.34 Pictures were taken with an
Olympus BX40 microscope (40x objective, NA 0.65) equipped
with an Olympus DP50 CCD camera and Viewfinder Lite 1.0
acquisition software. 
Hemoglobin content
Aliquots of approximately 2x106 cells of the original cultures
were removed and analyzed for hemoglobin content by photom-
etry as described.35 The relative ratios of HbA, HbA2 and HbF were
determined by HPLC (BioRad, Hercules, CA, USA).
RNA purification and quantitative RT-PCR analysis
Total RNA was extracted from cells using the TRI reagent
(Sigma). For quantitative real-time polymerase chain reaction (RT-
PCR) cDNA was synthesized from 1 μg of total RNA using ran-
dom hexamers and Superscript II (Invitrogen, Carlsbad, CA, USA).
RNase-free DNaseI (Invitrogen) was used to degrade contaminat-
ing DNA and primers were designed spanning an intron.
Quantitative PCR was performed as described in the Online
Supplementary Design and Methods. 
Statistical analysis
P values were calculated by the Mann-Whitney method and
ANOVA with Bonferroni’s correction using Stata11.0 (Stata Corp,
College Station, TX, USA). At least 5 independent biological sam-
ples were analyzed in triplicate in each group. 
Affymetrix microarrays
HEPs were lysed using the TRIzol Reagent (Invitrogen) and
RNA was isolated. Initial RNA yield and quality of the labeled frag-
mented cRNA were determined using the 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). A total of 5 μg of
cRNA was hybridized to U133 Plus 2.0 arrays, according to the
manufacturer's protocols (Affymetrix, Santa Clara, CA, USA).
Additional technical details and data analysis are described in the
Online Supplementary Design and Methods.
Results
HU induces hemoglobinization and reduces 
cell proliferation 
Human erythroid progenitor cells (HEPs) were expanded
from peripheral blood mononuclear cells as described.32,33
We first titrated HU treatment to determine the concentra-
tion-dependent effects on cell survival, proliferation, HbA
and HbF accumulation. We used cells from 2 unrelated
healthy donors for these experiments. HEPs were expanded
from peripheral blood mononuclear cells for ten days. HU
was added at Day 10 in concentrations ranging from 0 to
400 μM and cell proliferation was monitored daily.
Hemoglobin production, the percentage of HbA and HbF
and cell morphology were analyzed after 18 days when the
experiment was terminated (Online Supplementary Figure
S1). Cell density was maintained between 1-2 million/mL
by daily dilution and cumulative cell numbers were calcu-
lated. Increasing HU concentrations progressively
decreased cell proliferation. Only 400 μM HU was immedi-
ately toxic to the cells (Online Supplementary Figure S1A). HU
induced a concentration-dependent increase in total hemo-
globin that reached a maximum at 100 μM HU (Online
Supplementary Figure S1B). Analysis of hemoglobin subtypes
by HPLC indicated that HU increased the HbF percentage
concentration-dependent from 6% in non-HU treated to
9.7% in 200 μM HU-treated samples (Online Supplementary
Figure S1C). Using total Hb levels and relative ratios of HbA,
HbA2 and HbF, the accumulation of different hemoglobins
can be calculated (Online Supplementary Figure S1D). This
shows that both HbA and HbF were induced by HU.
Finally, we analyzed hemoglobinization at the cellular level.
Under proliferation conditions, addition of HU increased
the percentage of hemoglobinized cells from 30% in control
cells to 40% with 50 μM HU and up to 50% with 200 μM
HU in the cultures (Online Supplementary Figure S1E). Based
on these observations, and in agreement with previous pub-
lications,36-37 we conclude that HU induces erythroid differ-
entiation and hemoglobinization. Since the best response
with least cell toxicity was observed with 100 μM HU in
the cultures, we used these conditions for all other experi-
ments reported here. The selection of two groups of β-tha-
lassemia patients was based on either the complete absence
of response to HU treatment (NR) or a good response to HU
treatment resulting in transfusion-independence (R). The
XmnI (G)γ SNP (-158C>T) that has been associated with
increased HbF baseline expression is present in 19% of the
NR and in 69% of the R patient chromosomes. All of the
patients were screened for α- and β-globin gene mutations.
β-globin mutations were detected in all cases and no muta-
tions in the α-globin genes were present in the selected
patients (Online Supplementary Table S1).
Erythroblasts derived from responders are less 
sensitive to HU treatment and express higher HbF 
at baseline
First, we examined how HU sensitivity at the cellular
level corresponds to the response of β-thalassemic patients.
HEPs were expanded from blood mononuclear cells of the
16 selected β-thalassemic patients (Online Supplementary
Table S1). After ten days of culture, the HEPs were further
expanded in the presence or absence of 100 μM HU. Cell
numbers were monitored daily. The cells displayed similar
size distributions, indicative of similar differentiation
stages. This was confirmed by the similar expression of dif-
ferentiation markers (see below). Total hemoglobin produc-
tion, ratio of hemoglobin types, and cell morphology were
analyzed at Day 15 when the cultures were terminated.
The first difference observed between cultures derived
from NR-HEPs and R-HEPs was the relatively poor growth
rate of R-HEPs (38.7x106 vs. 10.6x106 cells, respectively)
(Figure 1A and B and Online Supplementary Figure S2).
Although proliferation of both NR- and R-HEPs was inhib-
ited by HU (declining to 7.6x106 vs. 4.8x106 cells, respective-
ly) (Figure 1A-C), the growth rate of R-HEP cultures was
affected much less than that of the NR-HEP cultures. We
conclude that NR-HEPs are much more sensitive to HU
treatment.
Total hemoglobin (in arbitrary units, a.u.) and the ratios of
fetal (HbF) versus adult (HbA) hemoglobin expression were
measured five days after the start of HU treatment (Day 15
of culture) and the absolute distribution of different hemo-
globins was calculated (Figure 1D). HU treatment slightly
altered the low expression of adult HbA in these tha-
lassemic cells, while the expression of HbF increased signif-
icantly (NR from 8 to 33 a.u., R from 106 to 248 a.u.). Since
the basal level of total hemoglobin is much higher in R-
HEPs, these cells express the highest HbF levels upon HU
treatment (Figure 1D). Analysis of HEPs treated with HU
for three days, stained for hemoglobin in combination with
F. Pourfarzad et al.
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histological dyes,34 showed that R-HEP cultures accumulat-
ed more hemoglobinized cells after HU treatment (25% in
R-HEPs vs. 10% in NR-HEPs; Figure 1E). Cultures of NR-
HEPs accumulated more pyknotic cells (20% in NR-HEPs
vs. 10% in R-HEPs; Figure 1E). 
In conclusion, when compared to R-HEPs, NR-HEPs are
more likely to succumb to cell death in response to HU.
Furthermore, although the fold-change in HbF levels upon
HU treatment is higher in NR-HEPs than that observed in
R-HEPs, the increase from the low baseline levels of HbF in
NR-HEPs does not yield adequate HbF levels in these cells. 
Responder HEPs constitutively express a 
stress-program that is induced by HU in non-responder
HEPs
In order to carry out gene expression profiling analysis,
HEPs were expanded for ten days and subsequently treated
with 100 μM HU or solvent for two days. RNA expression
profiles were compared between 8 R-HEP and 8 NR-HEP
cultures. The expression profiles of the samples were com-
pared using the SAM algorithm38 to identify HU response-
associated genes. While the expression of CD71 and GPA
were at similar levels indicative of similar stages of differen-
tiation in all samples, comparison of the expression profiles
between NR- and R-HEPs showed numerous differentially
expressed genes in the absence of HU (677 genes, 1105 dif-
ferentially expressed probe sets; Figure 2A and B). A striking
difference between the NR and R profiles is their response
to HU at the gene expression level. HU induced many
changes in gene expression of NR-HEPs (1887 genes, 2664
differentially expressed probe sets) whereas far fewer
changes were observed in R-HEPs (281 genes, 320 differen-
tially expressed probe sets), the majority of which were
shared with NR-HEPs (258 out of 281 genes; Figure 2A).
Complete lists of probe sets are provided in Online
Supplementary Table S2.
The expression data were used for cluster analysis clearly
separated R-HEPs from NR-HEPs (Figure 2B). Differentially
expressed gene enrichment analysis indicated that genes
involved in cellular proliferation and apoptosis were already
differentially expressed in R-HEPs compared to NR-HEPs
before HU treatment (Figure 2C). The untreated NR sam-
ples clustered separately from those treated with HU. In
contrast, the R samples clustered independent of HU treat-
ment. HU treatment barely affected the gene expression
profiles in samples R1, R3, R5, R7 and R8, and only moder-
ately in samples R2, R4 and R6 (Figure 2D). Interestingly,
upon HU treatment, the NR-HEP samples clustered more
closely to the R-HEP samples (Figure 2D). Thus, while HU
treatment had a major effect on the transcriptome of NR-
HEPs, it caused much less change in that of R-HEPs.
Differentially expressed gene enrichment analysis between
the two groups indicated that HU treatment caused differ-
ential expression of genes involved in apoptosis and cell
cycle regulation in NR-HEPs (Figure 2C and E). Collectively,
our data show that R-HEPs are adopted to constitutively
express a stress response program that is activated in NR-
HEPs upon exposure to HU.
The INK4b-ARF-INK4a locus is differentially regulated
between responders and non-responders
The INK4b-ARF-INK4a locus is known to be involved in
hematopoietic differentiation, proliferation, and stress
response.39-41 The probe sets on the microarrays do not dis-
criminate between the overlapping ORFs of p14ARF and
p16INK4a. Therefore, we analyzed expression of p15INK4b,
p14ARF and p16INK4a, encoded by the INK4b-ARF-INK4a
locus, in more detail (Online Supplementary Figure S3A).
Expression of p16INK4a was increased upon HU treatment in
both NR- and R-HEPs. Expression of p14ARF was at average
10-fold increased in NR-HEPs when compared to R-HEPs
independent of HU-treatment. These data suggest that the
effect of HU on the proliferation rate would be different
between the two groups of patients.
Stress response genes
From the array data we also selected a number of genes
with a role in the adaptation to stress that were consistently
differentially expressed between NR- and R-HEPs (Online
Supplementary Figure S3 and Table S3). Expression of these
genes was analyzed using qRT-PCR. Forkhead box O3
(FOXO3) is a transcription factor inducing genes that
enforce the oxidative firewall. Arginase 1 and 2 (ARG1,
ARG2) compete with NO synthase (NOS) for the substrate
L-arginine,42 and thereby protect against oxidative stress
from NO. Homeodomain interacting protein kinase 2
(HIPK2) is involved in apoptosis, differentiation and also
activation of CBP/P300.43,44 ARG2 and HIPK2 are known
FOXO3 target genes.45 These genes were all consistently
up-regulated in R-HEPs compared to NR-HEPs, and further
up-regulated upon treatment with HU in both groups
(Online Supplementary Figure S3B). Notably, expression levels
of ARG1 and ARG2 were higher in the untreated R-HEP
cultures than in HU-treated NR-HEP cultures and may have
a role in protecting R-HEPs from HU-induced cell death.
Kruppel like factor 10 (KLF10) was identified as a protein
that protects stromal cells and acute lymphoblastic
leukemia blasts against chemotherapy.46 KLF10 was
expressed at elevated levels in R-HEPs compared to NR-
HEPs, and reached similar levels in both groups upon HU
treatment (Online Supplementary Figure S3D).
Apoptosis genes
BCLXL (BCL2L1) protects erythroblasts from apoptosis.
Both in the absence and presence of HU, BCLXL levels were
higher in R-HEPs. BCLXL is under control of STAT5B47
which was decreased in NR-HEPs upon HU treatment,
although the difference was not as marked as that observed
for BCLXL (Online Supplementary Figure S3C and data not
shown). Whether BCL6 is directly involved in apoptosis is
currently not clear. During VDJ rearrangement in B cells it is
responsible for methylation of the ATR gene and thus pre-
vents the activation of the DNA damage response during
the rearrangement process.48 Expression of BCL6 is not
increased by HU in both groups, but it is expressed almost
10-fold higher in R-HEPs than in NR-HEPs (Online
Supplementary Figure S3C and Online Supplementary Table
S3).
γ-globin expression and erythroid maturation
Whereas stress erythropoiesis induces γ-globin expres-
sion,49-51 several transcription factors have been reported to
modify γ-globin expression, including KLF1, BCL11A and
SOX6.52 Expression levels of SOX6 are approximately 3.5-
fold higher in R-HEPs compared to NR-HEPs, whereas
expression of SOX4 was slightly less (Online Supplementary
Figure S3D and Online Supplementary Table S3). No signifi-
cant differences were seen in BCL11A expression between
the two groups. Expression of the γ-globin gene itself at the
transcript level was 4-fold higher in R-HEPs compared to
Hydroxyurea responsiveness in β-thalassemia
haematologica | 2013; 98(5) 699
NR-HEPs before HU treatment (Online Supplementary Figure
S3D). Finally genes important to maintain expansion of ery-
throblasts such as MYB,53 PRMT5,54 IKAROS55 and STAT56
remained constant (data not shown).
Merryweather-Clarke et al. reported global gene expres-
sion analysis of human erythroid progenitors.57 Comparison
of differentially expressed genes associated with terminal
erythroid differentiation (Online Supplementary Table S3)57
with the list of genes differentially expressed between
untreated R-HEPs and NR-HEPs revealed a considerable
number of overlapping genes (28%; 91 of 327 genes).
Interestingly, the expression dynamics of these genes in R-
HEPs was favoring terminal erythroid differentiation
(Figure 3A). Clustering analysis with these 91 genes clus-
tered R-HEPs and NR-HEPs in two distinct groups (Figure
3B). Collectively, these data are consistent with the notion
that compared to NR-HEPs, R-HEPs have an intrinsically
activated terminal erythroid differentiation program.
Discussion
Increased γ-globin gene expression ameliorates β-tha-
lassemia or SCD symptoms. However, γ-globin repression
is well controlled and its pharmacological alleviation is dif-
ficult to achieve. Proliferative stress, such as induced by HU,
can increase γ-globin expression, but not all patients
increase HbF to a therapeutic level that decreases their
dependency on regular transfusions. Here we show that
cultured cells from patients that respond or do not respond
to HU treatment display differential gene expression pro-
files already before HU treatment. We conclude from these
data that cells from responders as opposed to non-respon-
ders have adapted to constitutive stress conditions and dis-
play a propensity to proceed to the erythroid differentiation
program. We based these conclusions after characterization
of the proliferation, differentiation kinetics and gene expres-
sion profiles of erythroblasts expanded from β-thalassemia
patients at the extremes of clinical response to HU treat-
ment. The subjects were selected from a large cohort of
patients. All selected patients were on regular transfusion
according to their age and body weight (Online
Supplementary Table S1). The trial of the HU treatment pro-
tocol was over a period of 2-6 months at a dose of 5-20
mg/kg bodyweight per day with the aim of decreasing
transfusion dependency and clinical severity of the disease.
Two groups of patients were defined based on hemoglobin
level and transfusion dependency after HU treatment pro-
tocol. At this stage, blood samples were drawn from all
patients and their HEP cells expanded for ten days followed
by 0 and 100 μM HU for an additional five days to compare
proliferation, hemoglobin production and gene expression
profiles between the two groups. When compared to R-
HEPs, we observed that NR-HEPs were more sensitive to
HU treatment and that their initial HbF levels were lower.
HU treatment of NR-HEPs increased expression of a num-
ber of genes involved in cellular proliferation and apoptosis
F. Pourfarzad et al.
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Figure 1. Erythroblasts derived from responders are less sensitive to HU treatment and express higher HbF at baseline. NR-HEPs (A) grow
faster than R-HEPs (B). After HU treatment, growth curves of NR-HEPs (A) decline more than those of R-HEPs (B). (C) HU sensitivity curves
for NR-HEPs and R-HEPs, normalized by taking the ratio of cell proliferation of HU-treated cells over non-treated cells. (D) Hemoglobin induc-
tion by 100 μM HU (5 days) in NR-HEPs and R-HEPs; as in (C). (A-D) P<0.05 are indicated. (E) Representative cytospins of NR-HEPs and R-
HEPs treated with HU for three days. Cytospins were stained with histological dyes and neutral benzidine. Hemoglobinized cells are stained
brown. Pyknotic cells are indicated by arrows.  
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pathways, which is likely responsible for the observed
increase in cell death. They also expressed more HbF in
response to HU treatment. The fold-change in HbF is higher
in NR-HEPs than in R-HEPs, but the final HbF levels remain
lower in NR-HEPs due to their lower starting levels. The R-
HEPs express relatively high initial γ-globin levels, and this
increases further upon HU treatment. We observed that R-
HEPs and NR-HEPs already display significantly different
gene expression profiles at the start of the cultures. In con-
trast to the NR-HEPs, HU treatment had a relatively minor
impact on the global gene expression profiles of R-HEPs.
Based on these observations we suggest that in the cultured
cells the responder phenotype is associated with gene
expression signatures of terminal erythroid differentiation,
an activated stress response and protection from stress-
induced apoptosis. We suggest that these differential gene
expression profiles could potentially be used to distinguish
responders from non-responders in β-thalassemia patients
who have not yet received HU treatment. Whether such a
test could be performed directly on RNA isolated from
peripheral blood, or requires derivation of HEP cultures
first, must still be determined. 
Factors regulating γ-globin expression
The -158 XmnI SNP in the promoter of the γ-globin gene
has been linked to HbF expression.16 In our patient cohort,
11 of 16 (69% of chromosomes) of the responders carried
the -158 XmnI C>T SNP. Among the non-responders, only
3 of 16 (19% of chromosomes) carried this SNP. Although
there is a correlation between the presence of  -158 XmnI
SNP and base line HbF expression this SNP does not solely
determine HbF and HU response in this patient group. It is
very important to note that the most significant reported
SNPs are correlated with high HbF base line while HbF
responsiveness to HU is probably mediated by additional
mechanisms that protect hematopoietic cells against stress-
induced apoptosis and drives them to terminal erythroid
differentiation.
The array data reveal more genes differentially expressed
in R versus NR that may have an effect on the regulation of
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Figure 2. Responder HEPs constitu-
tively express a stress-program that
is induced by HU in non-responders
HEPs. (A) The number of differential-
ly expressed genes between NR-and
R-HEPs before and after HU treat-
ment. (B and C) Supervised cluster-
ing of differentially expressed genes
without (B) and with (C) HU treat-
ment. Responder: R; non-responder:
NR; HU treated: +HU. (D) Functional
annotation of differentially expressed
genes in R- versus NR-HEPs before
HU treatment. (E) Functional annota-
tion of differentially expressed genes
in R- versus NR-HEPs after HU treat-
ment. Functional annotation for bio-
logical processes was processed by
Ingenuity pathway analysis (P<
0.05).
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HbF, such as ID1 and HHEX (Online Supplementary Table S3).
We note that many genes involved in erythroid differentia-
tion are expressed at higher levels in R-HEPs (Figure 3).57
This suggests that R-HEPS have a propensity to enter the
terminal differentiation pathway while NR-HEPs maintain
a proliferative state. This difference may explain decreased
survival of NR-HEPs upon HU treatment, whilst R-HEPs
survive by undergoing terminal differentiation.
The role of stress factors in γ-globin expression
The low proliferation rate of the R-HEPs and their expres-
sion profiles suggest that these cells have adapted to perma-
nent stress conditions. This is supported by the observation
that HU treatment did not have a major impact on gene
expression in the R samples, while 2664 probe sets were
differentially expressed in response to HU in the NR sam-
ples. The most striking observation from the expression
profiles is the expression of stress proteins in R-HEPs. An
example validated by qRT-PCR is expression of FOXO3
(Online Supplementary Figure S3B and Online Supplementary
Table S3). FOXO3 is up-regulated during erythroid differen-
tiation35 and in response to various types of stress such as
ROS and DNA damage.58 The increased FOXO3 expression
in R-HEPs compared to NR-HEPs and the further upregula-
tion in response to HU indicate increased levels of cellular
stress. A number of FOXO3 target genes are also up-regu-
lated, for example HIPK2 and BTG1 (Online Supplementary
Table S3).45 Interestingly, the function of stress-induced
FOXO3 protein is not to induce cell death, but to increase
the potential of cells to prevent and repair oxidative damage
and to slow down the cell cycle to allow DNA repair before
replication.
The INK4b-ARF-INK4a locus is a master regulator of
cellular senescence, differentiation and apoptosis pro-
grams governed by the Rb and p53 signaling networks.
Genes of this locus are epigenetically silenced in
hematopoietic stem cells but become poised for transcrip-
tion as blood cells differentiate.41 Upregulation of p15INK4b
and p16INK4a, but not p14ARF, causes G1 arrests followed by
differentiation of hematopoietic progenitor cells.39,40 p14ARF
is involved in activation of the p53 apoptotic pathway.41
Thus we propose that the increased expression of  p16INK4a
upon HU treatment drives the R-HEPs and NR-HEPs
towards differentiation, but the relatively high expression
of p14ARF in NR-HEPs, as well as other components of the
p53 mediated apoptosis pathway such as CDKN1A and
MDM2 (Online Supplementary Figure S3A and Online
Supplementary Table S3), results in apoptosis rather than
terminal differentiation. These two differential HU effects,
one due to increased apoptosis and the other due to more
differentiation, result in similar proliferation rates of NR-
HEPs and R-HEPs (7.6x106 vs. 4.8x106 cells, respectively,
Figure 1A and B). 
HU is a ribonucleotide reductase inhibitor that stalls cells
in S phase.59 Stalled replication forks are potent inducers of
senescence or apoptosis, but possibly also of HbF. Defects
in the Fanconi anemia pathway result in increased replica-
tion fork stalling. It is therefore interesting to note that
Fanconi anemia is associated with high HbF levels.60
Importantly, a stalled replication fork activates ATR kinase,
which is crucial to all downstream events. Increased expres-
sion of BCLXL (BCL2L1, Online Supplementary Table S3)
could also contribute to enhanced survival of R-HEPs in the
presence of HU. In normal erythroid progenitors BCLXL is
induced by EPO to maintain viability of erythroid cells dur-
ing terminal maturation.61
ARG 1 and ARG 2
HU increases NO production through phosphorylation
and activation of nitric oxide synthetase (NOS).62 Although
NO has been implicated in upregulation of HbF through
activation of γ-globin expression,63 NO also inhibits growth
of erythroid primary cells and colony cultures.64 Arginase
hydrolyzes L-arginine to urea and L-ornithine in the urea
F. Pourfarzad et al.
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Figure 3. Expression
dynamics of substantial
numbers of differential-
ly expressed genes in
responder HEPs are
towards terminal ery-
throid differentiation.
(A) Overlap of differen-
tially expressed genes
in R-HEPs (R) versus
NR-HEPs (NR), with
genes involved in the
erythroid differentiation
program (28%; 91 of
327).57 (B) Clustering
analysis of genes
involved in the ery-
throid differentiation
program that are also
differentially expressed
between R and NR-
HEPs.
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cycle and inhibits nitric oxide (NO) production via compe-
tition with NOS for the substrate L-arginine.42 During ery-
throid differentiation NO levels decrease significantly.65 NO
is inhibited more by fetal RBCs when compared to adult
RBCs suggesting that fetal RBCs have a higher level of NO
scavengers.66 On the other hand, high NO concentrations
promote apoptosis, while low NO concentrations result in
resistance to apoptosis.
The Arginase 1, ARG1, Arginase 2, ARG2, and argini-
nosuccinate synthetase 1, ASS1 genes are differentially
expressed between NR-HEPs and R-HEPs. Their expression
is 10.2-, 2.4- and 1.9-fold increased in R-HEPs compared to
NR-HEPs (Online Supplementary Figure S3B and Online
Supplementary Table S3). In an SNP association study,
ARG1/ARG2, ASS1, NOS1 and NOS2A were reported to
be significantly associated with response to HU treatment.17
Moreover, ARG1 and ARG2 SNPs were also found to be
significantly associated with the change in HbF and maxi-
mum HU tolerated dose in SCD patients.22 This suggests
that high expression of ARG1, ARG2 and ASS1 protects
hematopoietic progenitor cells against excessive amounts of
NO after HU treatment to prevent apoptosis, and scavenge
the extra NO at later stages of differentiation.
In conclusion, the biological and molecular analysis of
erythroblast cultures of β-thalassemia patients suggests that
several mechanisms are involved in high HbF expression
and HU responsiveness. Although the basal HbF level is cor-
related with polymorphisms such as the XmnI (Gγ) SNP (-
158C>T), cell survival, stress response and propensity
towards terminal erythroid differentiation are also playing
important roles in β-thalassemia patients HU response. R-
HEPs, compared to NR-HEPs, proliferate at a slower rate,
are intrinsically poised to undergo terminal erythroid differ-
entiation, and have a constitutively activated stress
response. Thus, our data indicate that drugs activating the
stress response may increase HbF, provided that cell survival
and differentiation are not compromised. 
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